The 13thu The Aging Research & Drug Discovery Meeting (ARDD), the world’s largest conference dedicated to longevity biotechnology, will be held October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University. Marking the high-profile kickoff to Boston Longevity Week, this landmark event is officially hosted by Insilico Medicine, which also anchors the conference as a Tier 1 sponsor along with Eli Lilly.
As the science of longevity moves rapidly from theoretical concepts to multibillion-dollar therapeutic pipelines, ARDD 2026 is the premier global nexus connecting basic science, clinical research, big pharma and institutional investors. Moving the conference to Boston—the global epicenter of biomedical innovation—reflects the industry’s evolution into mainstream medicine.
Building on the massive momentum of previous years—including ARDD 2025 in Copenhagen, where leadership from Eli Lilly and Novo Nordisk discussed the profound longevity potential of GLP-1 receptor agonists at Nature Biotechnology—the 2026 conference reinforces aging research as a cornerstone of healthcare. Leading pharmaceutical companies are now actively developing commercial programs targeting fibrosis, immunology, CNS, cardiometabolic disease, anti-muscle destruction and cellular regeneration.
The comprehensive 2026 program features highly specialized daily tracks designed to drive clinical translation and industry development:
-
October 1: Clinical Development Day and Longevity Medicine Track
-
October 2: AI on the drug discovery track
-
October 3: Future Technology Track
In addition to the main scientific program, the conference will host multiple high-profile, invitation-only receptions to facilitate networking among global decision-makers. Confirmed speakers already include executives from 10 of the world’s leading pharmaceutical companies.
The conference is led by an elite of international chairs representing leading academic and scientific institutions: Vadim Gladyshev and Jesse Poganik (Harvard Medical School). Alex Zhavoronkov (Insilico Medicine); Morten Scheibye-Knudsen and Daniela Bakula (The University of Copenhagen); Evelyne Bischof (Sheba Longevity Centre); and Maximilian Unfried (National University of Singapore). Further enhancing the meeting’s influence on the global health economy, the McKinsey Institute of Health joins ARDD 2026 as the sole knowledge partner.
Reflecting its global scale, ARDD 2026 has secured support from a number of prominent biotech and financial institutions. Tier 1 participants Eli Lilly and Insilico Medicine are Tier 3 sponsors AbbVie, BioAge, Human Longevity, Tally Health, Maxwell Biosciences, Gordian, TruDiagnostic and Cyclarity Therapeutics. Synaro Capital is supporting the event as a Tier 4 sponsor, along with Tier 5 sponsors including Morgan Stanley, Healthy Longevity, Intrinsic Capacity and QuadraScope.
To ensure early billing and receive immediate notification when the registration system opens, prospective participants are encouraged to join the priority waiting list. Please visit the official registration portal at or learn more at agingpharma.org.
Sponsorship opportunities remain available at multiple levels, including customized packages for industry partners looking to connect with decision makers from venture capital, academia and big pharma.
